These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38335813)

  • 1. Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma?
    Bernardi L; Roesel R; Aghayan DL; Majno-Hurst PE; De Dosso S; Cristaudi A
    Cancer Treat Rev; 2024 Mar; 124():102696. PubMed ID: 38335813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Score-Matched Cohort Study.
    Hirokawa F; Ueno M; Nakai T; Kaibori M; Nomi T; Iida H; Tanaka S; Komeda K; Hayami S; Kosaka H; Hokuto D; Kubo S; Uchiyama K
    J Gastrointest Surg; 2022 Apr; 26(4):772-781. PubMed ID: 34664190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?
    Hirokawa F; Asakuma M; Komeda K; Shimizu T; Inoue Y; Kagota S; Tomioka A; Uchiyama K
    Surg Today; 2019 Jan; 49(1):82-89. PubMed ID: 30255329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy versus upfront surgery as the initial treatment for patients with resectable, synchronous colorectal cancer liver metastases.
    Lee JM; Han YD; Cho MS; Hur H; Lee KY; Kim NK; Min BS
    J Surg Oncol; 2023 Sep; 128(4):549-559. PubMed ID: 37288777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases.
    Ninomiya M; Emi Y; Motomura T; Tomino T; Iguchi T; Kayashima H; Harada N; Uchiyama H; Nishizaki T; Higashi H; Kuwano H
    Int J Clin Oncol; 2021 Dec; 26(12):2255-2264. PubMed ID: 34519930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The survival benefit of neoadjuvant chemotherapy for resectable colorectal liver metastases with high tumor burden score.
    Yonekawa Y; Uehara K; Mizuno T; Aiba T; Ogura A; Mukai T; Yokoyama Y; Ebata T; Kodera Y; Nagino M
    Int J Clin Oncol; 2021 Jan; 26(1):126-134. PubMed ID: 33074351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topics related to neoadjuvant chemotherapy for resectable liver metastases from colorectal cancer.
    Ke S; Zhan S; Zhu H; Yan D
    J BUON; 2018; 23(2):296-301. PubMed ID: 29745068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis.
    Ono K; Abe T; Oshita A; Sumi Y; Yano T; Okuda H; Kurayoshi M; Kobayashi T; Ohdan H; Noriyuki T; Nakahara M
    World J Surg Oncol; 2021 Apr; 19(1):97. PubMed ID: 33820549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
    Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
    Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
    Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: a single-institution retrospective study.
    Kitano Y; Ono Y; Kobayashi K; Oba A; Sato T; Ito H; Inoue Y; Shinozaki E; Yamaguchi K; Saiura A; Baba H; Takahashi Y
    HPB (Oxford); 2024 Feb; 26(2):282-290. PubMed ID: 37985325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D; Hollande F; Michael M; Hayes I; Heriot A; Knowles B; Thomson B
    ANZ J Surg; 2021 Jun; 91(6):1196-1202. PubMed ID: 33543551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Factors for the Survival Outcomes of Preoperative Chemotherapy in Patients with Resectable and Borderline Resectable Colorectal Cancer with Liver Metastasis.
    Inworn N; Senavat P; Aleenajitpong N; Chingchaimaneesri M; Siripoon T; Srirattanapong S; Suragul W; Ngamphaiboon N
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3037-3047. PubMed ID: 37774055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentre study of perioperative
    Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
    BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy for resectable colorectal liver metastases: what is the evidence? Results of a systematic review of comparative studies.
    Nigri G; Petrucciani N; Ferla F; La Torre M; Aurello P; Ramacciato G
    Surgeon; 2015 Apr; 13(2):83-90. PubMed ID: 25257725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Zhu D; Zhong Y; Wei Y; Ye L; Lin Q; Ren L; Ye Q; Liu T; Xu J; Qin X
    PLoS One; 2014; 9(1):e86543. PubMed ID: 24466143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative second-line chemotherapy is beneficial for resectable liver metastases that occur during or early after adjuvant chemotherapy for colorectal cancer.
    Xu D; Zhu HB; Wang YY; Jin KM; Yan XL; Li J; Wang K; Xing BC
    Int J Colorectal Dis; 2022 Apr; 37(4):805-814. PubMed ID: 35188594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.